Inactivation of kupffer cells after prolonged donor fasting improves viability of transplanted hepatic allografts
Howard N. Sankary, Anita Chong, Preston Foster, Esther Brown, Jikun Shen, Robert Kimura, Guarimella Rayudu, James Williams – 1 October 1995 – Data from recent studies suggest that donor fasting imparts a beneficial effect on the viability of transplanted hepatic allografts. Because starvation may temporarily inactivate Kupffer cells, and because these cells are the likely mediators of liver injury after prolonged preservation‐reperfusion, the purpose of this study is to establish a link between improved organ viability and Kupffer cell inactivation caused by donor allograft fasting.
Anti‐hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution” assay
Rudolf A. Heijtink, Johannes Kruining, Yvonne A. M. Weber, Robert A. de Man, Solko W. Schalm – 1 October 1995 – Two human monoclonal antibodies with anti‐hepatitis B activity were investigated separately and as a mixture by means of an “inhibition in solution” assay. With this assay the capacity of anti‐HBs antibodies to inhibit the binding of hepatitis B surface antigen (HBsAg) with solid‐phase anti‐HBs (Ausria II, Abbott Laboratories) was studied. Both HBsAg of different subtypes and purified Dane particles were used.
Parenchymal and nonparenchymal uptake of technetium‐99m, indium‐111, and iodine‐125 low‐density lipoprotein in the normal and estradiol‐stimulated rat liver: Tracer validation for quantitative low‐density lipoprotein scintigraphy
Thomas Leitha, Anton Staudenherz, Marcela Hermann, Manfred Hüttinger, Bernhard Gmeiner – 1 October 1995 – This study quantifies the parenchymal and nonparen‐chymal uptake of technetium‐99m (99mTc)‐ and indium‐III (111In)‐low‐density lipoprotein (LDL) in different states of hepatic LDL‐receptor activity to validate quantitative LDL scintigraphy. Iodine‐125 (125I)‐LDL was used as reference tracer.
Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol‐induced liver disease
Onni Nlemelä, Seppo Parkkila, Seppo Ylä‐herttuala, Jesus Villanueva, Boris Ruebner, Charles H. Halsted – 1 October 1995 – The pathogenesis of alcohol‐induced liver disease involves the adverse effects of ethanol metabolites and oxidative tissue injury. Previous studies indicated that covalent protein adducts with reactive aldehydes may be formed in alcohol consumers.
Ciprofloxacin and long‐term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial
Alain Rolachon, Laurent Cordier, Yannick Bacq, Jean‐Baptiste Nousbaum, Anne Franza, Jean‐Claude Paris, Serge Fratte, Benoit Bohn, Pascal Kitmacher, Jean‐Paul Stahl, Jean‐Pierre Zarski – 1 October 1995 – The aim of this prospective double‐blind study was to evaluate the value of long‐term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (<15 g/L).
Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia
Massimo Siciliano, Daniele Tomasello, Alessandro Milani, Bianca Maria Ricerca, Sergio Storti, Lodovico Rossi – 1 October 1995 – Chronic anemia is frequently observed in patients affected by cirrhosis. To investigate the possible role of erythropoietin (Epo) in the pathogenesis of anemia in cirrhosis, we measured the immunoreactive Epo levels and the respective hemoglobin (Hb) concentrations in 48 anemic and nonanemic cirrhotic patients and in a control group of healthy subjects and patients with iron‐deficiency anemia.
Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C
Shirley Coverdale, Karen Byth, Jacqueline Field, Christopher Liddle, Rita Lin, Geoffrey C. Farrell – 1 October 1995 – To determine whether hepatic metabolic function affects the response to interferon treatment, we measured antipyrine clearance (APC) in 85 patients with chronic active hepatitis C and compared the results with treatment outcome.
Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B
Yosuke Morimitsu, David E. Kleiner, Hari S. Conjeevaram, Chu Chieh Hsia, Adrian M. Di Bisceglie, Edward Tabor – 1 October 1995 – The effect of interferon alfa (IFN‐α) therapy on the expression of transforming growth factor alpha (TGF‐α) in the liver during chronic hepatitis B was investigated. Serial liver biopsy specimens were evaluated from 35 patients who had participated in a randomized, controlled trial of recombinant human IFN‐α for the treatment of chronic hepatitis B.
Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture
Jordi Muntané‐Relat, Jean‐Claude Ourlin, Jacques Domergue, Patrick Maurel – 1 October 1995 – We have investigated the effect of cytokines, including interleukin‐6 (Il‐6), interleukin‐1α (Il‐1α), and tumor necrosis factor‐alpha (TNF‐α), on the inducible expression of cytochrome P450s (CYP) CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. The ability of these cultures to mimic the acute phase response when stimulated with cytokines was evaluated using immunoblotting to measure the production of albumin, ferritin, fibrinogen, and ceruloplasmin.